sanofi – Page 4

Sanofi, Regeneron’s IL-33 Drug Fails One of Two COPD Studies, Casting Doubt on FDA Approval Timeline

7 months ago talkbio0Tagged AERIFY-1, AERIFY-2, Approved, Clinical Trials, COPD, IL33 protein, human, itepekimab, Regeneron, sanofi, United States Food and Drug Administration

Sanofi; Regeneron; COPD; itepekimab; IL-33; Phase 3 trials; AERIFY-1; AERIFY-2; FDA approval; clinical trial results

Sanofi Opens $130M ‘Flagship’ US Office Facility in Morristown, New Jersey

7 months ago talkbio0Tagged Corporate, flagship office, Health care facility, innovation, Market, Morristown, sanofi, U.S.

Sanofi; Morristown; flagship office; $130 million; healthcare; innovation; New Jersey; US market; corporate hub

Sanofi Acquires Vigil Neuroscience for $470 Million, Bolstering Alzheimer’s Drug Pipeline

7 months ago talkbio0Tagged Acquisition, Agonist, Alzheimer 's disease, Microglia, Neurodegenerative Disorders, Phase 2 Trials, sanofi, TREM2, VG-3927, Vigil Neuroscience

Sanofi; Vigil Neuroscience; acquisition; Alzheimer’s disease; TREM2 agonist; VG-3927; microglia; neurodegenerative disease; Phase 2 trials; biotech deals

Sanofi Commits $20 Billion to U.S. R&D and Manufacturing by 2030

7 months ago talkbio0Tagged domestic partnerships, drug launches, Investments, Manufacturing, R&D, sanofi, Surgical construction, United States

Sanofi; $20 billion investment; U.S. manufacturing; R&D; job creation; drug launches; domestic partnerships

Sanofi Announces $20 Billion US Investment Over Five Years

7 months ago talkbio0Tagged Big Pharma, development aspects, domestic partnerships, Drug Industry, Investments, Manufacturing, research, sanofi, Surgical construction, tariffs, U.S.

Sanofi; $20 billion investment; US pharmaceutical industry; manufacturing; research and development; tariffs; job creation; Big Pharma; domestic partnerships

Sanofi Commits $20 Billion to US Expansion Amid Industry-Wide Investment Surge

7 months ago talkbio0Tagged drug production, Industry, Investments, pharmaceutical manufacturing, R&D, sanofi, supply chain, Surgical construction, trends qualifier, U.S.

Sanofi; US investment; pharmaceutical manufacturing; R&D; drug production; job creation; supply chain; industry trends

Sanofi axes IGM pact, sparking 80% layoffs at the biotech and facility closures

7 months ago talkbio0Tagged Biosciences, Biotech Layoffs, Collaboration termination, Facility (object), IgM antibodies, Immunoglobulin M, Immunology, Inflammation, Neoplasms, Reparative closure, sanofi

Sanofi, IGM Biosciences, collaboration termination, biotech layoffs, facility closures, IgM antibodies, immunology, inflammation, oncology

Sanofi’s Altuviiio closing in on blockbuster status, Dupixent sales surge

8 months ago talkbio0Tagged Altuviiio, Dupixent, Sales - occupational activity, sanofi, United States Food and Drug Administration

Altuviiio, Sales – occupational activity, sanofi, Dupixent, United States Food and Drug Administration

Sanofi, Novartis CEOs lambast EU price control as Trump reportedly weighs drug cost parity with other nations

8 months ago talkbio0Tagged CEOs, EU, Financial cost, Investments, Market, nations, Novartis, Parity, Pharma, Prices, sanofi, Transplant Registry Unified Management Program, U.S.

EU, Novartis, CEOs, Transplant Registry Unified Management Program, Financial cost, Parity, sanofi, Investments, Prices, Pharma, Market, nations, U.S.

Sanofi pens $1.8B research deal for 2 bispecific antibodies aimed at autoimmune, immunology

8 months ago talkbio0Tagged Antibodies, Bispecific, Autoimmune, Collaboration, development aspects, Earendil Labs, Immunology, Inflammatory Bowel Diseases, sanofi

Antibodies, Bispecific, Autoimmune, Inflammatory Bowel Diseases, sanofi, Earendil Labs, Immunology, Collaboration, development aspects